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Objective: To survey lead colposcopists to explore the extent to which patients are currently being invited to discuss the results of their invasive cervical cancer review, the reasons why this might not be happening and the clinician experience.
Methods: An online survey was sent to lead colposcopists across England. They were asked whether they offered the review to patients, if they did how they did so and what their experience was and if they did not, why not.
Results: There was a 68.5% (N=122) response rate, with 53% of respondents currently offering the review meetings. Patients were predominantly invited to the review meeting face to face and clinicians’ experiences were mixed with a variety of positive and negative aspects to the meetings given. For those clinicians not currently offering a review meeting, there were a variety of reasons: 25% cited a lack of awareness of the guidelines, 19% time constraints, 12% a fear of causing additional distress, and 2% a fear of litigation. Open-ended responses demonstrated a considerable amount of misunderstanding about the process.
Conclusion: Despite NHSCSP guidelines, not all clinicians offer review meetings to patients and those who do offer them do not always offer them to all women. Patient research needs to be conducted to explore the value of the meetings further,and there is a need to do more to engage clinicians in the process.
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Introduction
In 2006 the National Health Service Cervical Screening Programme (NHSCSP) for England published a guidance document Audit of Invasive Cervical Cancer1. The purpose of the document was to “define a national protocol for audit of cases of invasive cervical cancer” (p.1) which would facilitate identification of good practice as well as areas for improvement. The audit process identified that for each woman diagnosed with cervical cancer, a review of her cytology slides from the past 10 years, colposcopy notes and any histology specimens should be conducted with a view to monitoring how effective the screening programme is, as well as identifying areas for improvement and best practice for dissemination. The document stated that as part of the audit process, the “treating gynaecologist or oncologist reports review findings to patient” (p.6). A meeting to discuss the review findings was intended to provide patients with information about their screening history and clinical management with the rationale being that women would want this information and that complaints and claims are less likely if the process is perceived as transparent and if the patient receives an apology or sympathy for their experience. 
Whilst patient compliance is a major contributing factor in the development of cervical cancer, other issues often emerge from the reviews, such as cytological under-call. In order to assist with providing patients with potentially distressing additional information about their cervical cancer at an already challenging time, a sister publication Disclosure of Audit Results in Cancer Screening: Advice on Best Practice2 was published in the same year and was concerned with how best to disclose the results of cervical cancer history reviews to patients. This document used the breaking bad news literature as the basis for the guidance it provided, which covered what information patients should be given and how, the timing of the disclosure and who should conduct the review meeting. 
Despite the requirement for clinicians to offer a discussion about the review of their screening history to all patients and the guidance provided to support this, there is emerging anecdotal evidence, primarily arising from the external quality assurance (QA) process that disclosure is patchy, with some Trusts being selective about the women invited for a review meeting whilst other Trusts do not offer such meetings at all3, 4. Those Trusts that are selective may have very well-motivated reasons for not inviting certain women to a review meeting. For example, Prabaker et al (2012) reported choosing not to invite women to a review meeting who have previously declined an invitation to attend cervical screening since this “may be detrimental to their psychological well-being” specifically, wishing “to avoid the feeling of irresponsibility or guilt on the part of the patients” (p169). 
The Disclosure document suggests that there may be also reservations surrounding disclosing prior mismanagement of abnormalities, including concern that the patient may not want the information; when the best time to disclose to a patient might be; who the best person for the job is and the potential distress that clinicians might experience. However, in addition to the potential benefits of disclosure outlined above, Sherman et al (2013) also suggest that when examining evidence from the literature surrounding discussing cancer and disclosing medical errors, other potential benefits emerge, such as increased trust, closure and better perception of care. In order to manage the apparent gap between clinician concerns about disclosure and the potential benefits that it may lead to, it is necessary to understand the precise nature of clinicians’ concerns5.
The aim of this study was to investigate to what extent meetings discussing the review findings are offered to patients and in those cases where they aren’t offered, why this is the case. Although the 2006 Audit document refers to the “treating gynaecologist or oncologist”, the Disclosure document refers to the “the clinician treating the patient” (p5). Whilst other clinicians may be involved in this process, it is frequently the lead colposcopist who is in a position to conduct the review meeting and/or oversee its implementation within their colposcopy service. In order to explore issues surrounding the review meeting, we therefore decided to survey lead colposcopists across England.
Methods
An email with a link to an online survey was sent to 178 lead colposcopists across England, following consultation with the British Society for Colposcopy and Cervical Pathology (BSCCP)​[1]​. A 12 item self report survey was used. The first four questions were demographic in nature: date of birth, gender, region, and optionally, the name of the Trust that they worked for. The fifth question asked whether they currently offered women invasive cervical cancer review meetings. If they said yes, they were asked a closed question concerning how they invited women to a review meeting (including an ‘other’ option), followed by open ended questions asking what criteria were used to select which women to invite, what the positive and negative aspects of the review meetings were and approximately how many women over the past five years had been invited to such a meeting and had attended such a meeting. For those respondents indicating that they did not currently offer review meetings, they were asked a closed question about what the reasons were (including an ‘other’ option). All respondents were then asked if they had any other comments regarding the invasive cervical cancer review meetings.
Results
There was a 68.5% (N=122) response rate​[2]​. Of the 122 respondents, 53% (N=65) indicated that they currently offered review meetings to patients whilst 47% (N=57) did not. Of those who did offer review meetings, 58% (N=38) invited women to the review meeting face to face, 31% (N=20) invited them by letter and 8% (N=5) used a leaflet.  No one used email or the telephone. One respondent commented that the invite was not issued by themselves, and one respondent said that a letter was sent to patients telling them that they would be informed of the findings but they were not given the option of a meeting to discuss them.
When asked about the criteria used to invite the women, there were 61 responses. 57% (N=35) respondents indicated that they invited all women, a further 31% (N=19) indicated that they invited all women with some caveats: as long as the women had had a smear test or colposcopy in the past (23%, N=14); as long as a false negative smear/a problem was identified (3%, N=2); as long as an audit had been completed (3%, N=2); all women with invasive cancer greater than micro-invasive 1a (2%, N=1); 7% (N=4) indicated that they would conduct a review meeting in response to a patient request (including in response to a letter of invitation). A further 5% (N=3) mentioned miscellaneous criteria such as following national guidelines, identification by Health and Care Professions Council (HCPC), patient specific criteria (unspecified).  
Translating this into practice, 51% (N=33) reported offering 15 or fewer review meetings over the past 5 years. 29% (N=19) have offered between 15 and 100 meetings, whilst 3% (N=2) reported offering 100 or more meetings. 2% (N=1) reported that 4 meetings were offered over the preceding year. 15% (N=10) respondents did not provide a numerical answer. There were fewer meetings taken up than offered: 83% (N=54) respondents reported conducting 10 or fewer review meetings in the past 5 years, with 10 of them reporting that none had taken place. 9% (N=6) reported between 20 and 75 meetings having taken place. 8% (N=5) of respondents did not provide a numerical answer.
Respondents were asked what they felt the positive and negative aspects of the review meetings were. These were open ended questions and responses were grouped into categories. Positive aspects of the review meetings were identified as follows: 43% (N=28) of respondents indicated that transparency/providing reassurance about the system was a positive aspect of the process, 29% (N=19) indicated that it was useful for the system and clinicians, 15% (N=10) said that it gave them a chance to provide information to patients or to have further discussion, 12% (N=8) felt there were no positive, only negative aspects to the process, and 6% (N=4) mentioned that it was an opportunity to provide support or closure to the patient. Two respondents (3%) indicated they had not yet conducted a meeting and one respondent (2%) indicated that all aspects were positive.
Several negative aspects of the review meetings were identified as follows: 55% (N=36) of clinicians were concerned about the negative impact/distress caused to patients, 29% (N=19) had professional anxieties, such as a fear of litigation, 18% (N=12) said there were no negative aspects, 6% (N=4) indicated that it was time-consuming, and 5% (N=3) felt the process was pointless. One respondent (2%) indicated they had not yet conducted a review meeting, one (2%) commented on the process and two (3%) were vague. 
Of the 47% (N=57) of respondents who indicated that they do not currently offer review meetings to patients, 25% (N=14) said they were not aware of the guidelines advising them to do so, 19% (N=11) said this was due to time constraints, 12% (N=7) feared causing additional distress to patients, whilst 2% (N=1) indicated that they feared being sued. 60% (N=34) took the opportunity to indicate other reasons and these reasons were classified as follows: 28% (N=16) believed it was someone else’s responsibility and 9% (N=5) indicated that it was up to the patients to initiate the request. 5% (N=3) were about to start the process, two following QA team reports, 9% (N=5) responded to indicate that there was in fact some form of audit in place and the remaining 9% (N=5) either used to do it and stopped, had yet to get all colleagues on board or had not received details about individual reports.
Lastly, all participants were given the opportunity to provide any further comments about the review meeting. Some of these repeated points identified above. Broadly the additional comments made fell into the following categories: a misunderstanding of the process (N=21), a desire for additional support and information (N=14), support for the process (N=14), the review should be initiated by the patient (N=4), concerns about litigation and professional anxiety (N=4), a feeling that the process was pointless/a waste of money (N=3). There were an additional 10 comments either about the survey itself (N=3), or with very general observations for example, about aspects of the screening process.    
Discussion
These data provide the first concrete evidence to explore why not all Trusts offer the invasive cervical cancer review to patients and that many of those that do are selective about the women they are offered to. Only 53% of respondents disclose the review results but anecdotal evidence suggests that the true figure is likely to be even lower. For those respondents who did not offer the review, there were four main issues preventing them from doing so:  time constraints, lack of awareness or misunderstanding of the guidelines (including the perception that it was someone else’s job) and a fear of causing additional distress to patients; a less identified issue was the fear of litigation.  The low awareness or misunderstanding of the guidance found in this study is not easy to understand as it is readily available alongside all other documents of the programme.  It could be because the guidelines are not directed at a particular professional group and therefore lack professional ownership, and/or because there has been a lack of emphasis on their implementation in addition to a lack of engagement in the process from some clinicians. The issues raised by those who do not offer the review resonate well with the negative aspects of the review meeting identified by respondents who do conduct them. Causing distress to patients was the most often mentioned issue, with professional anxiety including the fear of litigation coming second. Time constraints were also mentioned.
As yet there has been no research investigating the patient perspective. As Gallagher et al (2003) found when exploring patients’ and clinicians’ attitudes towards the disclosure of hypothetical medical errors, clinicians preferred to ‘choose their words carefully’ and feared a loss of patient trust, whilst patients were unanimous in their belief that such errors should be disclosed and that this disclosure would enhance trust and provide reassurance6. These positive aspects are reflected in the positive aspects of the review meeting identified by respondents in the current study, some of who felt that it increased transparency as well as giving clinicians an opportunity to provide support and information to patients, presumably thus increasing communication. If it were the case that patients who had undergone review meetings found them to be beneficial, then it would be prudent to encourage clinicians to reconsider the meetings; however as identified by several respondents, this could helpfully be accompanied by additional guidance and support. Several respondents felt that the patient needed to initiate the meeting. However, the women most likely to have a diagnosis are arguably also the least likely to ask for a review meeting due to the socio-demographic factors that increased their risk in the first place and thus may well be missing out on any benefits that such a meeting might provide.
Whether or not patients find the review meetings useful, it is not something that is widely taken up by patients who are offered them. 83% of respondents who do offer review meetings report carrying out 10 or fewer in the past five years. It is well known that patients have different psychological coping styles7 which affect whether they prefer more or less information about their condition, and it may well be that this is impacting the rate of uptake of meetings offered. Alternatively, with 58% of clinicians who offer the meetings inviting women face to face, it is unclear whether the timing of the invitation might reduce the uptake – if women are told about the review at the same time as diagnosis for example, they may well feel overwhelmed with information and focus on their treatment, forgetting about the review. If sent a letter or given a leaflet about the review meeting, it is possible that women can revisit the possibility of a review at a later date. 
Strengths and weaknesses of the research
This is the first survey of its kind to try and explore the positive and negative aspects of the screening history review meeting from a clinical perspective. This fact is a strength of the paper but also leads to some weaknesses. There remains uncertainty surrounding the conducting of these meetings through rather vague phrases in the national guidance such as “the clinician treating the patient”2. As a result, by choosing to focus on lead colposcopists as the clinicians most likely to be offering disclosure, we have inevitably not included all the clinicians who are involved in conducting these meetings or key staff such as hospital-based cervical screening programme co-ordinators whose role encompasses overall responsibility for co-ordinating audit data within each Trust. However we have captured a range of experiences of and opinions about the process which are likely to be experienced by other clinicians. The survey was carried out between June 2013 and August 2014. Commissioning of cervical screening became standardised across England from April 2013 with the introduction of a national specification (current version is for 2015/168) and transfer of commissioning responsibility to the newly created NHS England.  Within the specification is a requirement for all Trusts carrying out cervical screening to undertake required national and regional audits.  This should assist commissioners in supporting actions arising from QA visits where a lack of compliance with the invasive cervical cancer audit guidance is identified. However, in the first instance, highlighting the issues identified through this research to professionals involved in the NHSCSP should raise awareness and generate improvement in overall compliance. 
Conclusion
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^1	  Whilst practices vary from Trust to Trust such that it is not always the lead colposcopist who has responsibility for inviting the patient to a review meeting, it was felt that this would provide an indication of the scale of disclosure practices as well as some insight into the reasons behind non-disclosure.
^2	  We sent the survey out twice because the first email list was found to be incomplete. The survey went to lead colposcopists in all regions across England. The response rate is calculated by dividing the combined number of responses (minus suspected duplicates) by the sum of the  email addresses in the 2nd up to date list and the emails for the North West region in the 1st list since they did not produce updated email addresses in the necessary time frame. Three suspected duplicate responses were removed. Two further suspects were left in as their responses had changed. 
